Biologics CDMO Market Expected to Reach USD 30.45 Billion by 2029, Driven by Rising Demand for Biologic Drugs and Innovation in Biomanufacturing

Mordor Intelligence has published a new report on the Biologics CDMO Market offering a comprehensive analysis of Key trends, growth drivers, and major players in the industry.

The Biologics CDMO Market is projected to be valued at USD 18.17 billion in 2024 and is expected to reach USD 30.45 billion by 2029, growing at a compound annual growth rate (CAGR) of 10.87% over the forecast period from 2024 to 2029.

Report Overview - https://www.mordorintelligence.com/industry-reports/biologics-contract-development-and-manufacturing-organization-cdmo-market

Key Trends Shaping the Biologics CDMO Market

Growing Demand for Biologic Drugs: Biologic drugs, including monoclonal antibodies, vaccines, and gene therapies, are witnessing a surge in demand as they offer targeted treatment options for complex diseases. The increasing prevalence of chronic conditions and the shift towards personalized medicine are driving the need for biologics, which in turn is fueling demand for CDMO services. As more pharmaceutical companies invest in biologic drug development, CDMOs are becoming indispensable for providing the necessary infrastructure, expertise, and scalability for large-scale biologic production.

Expansion of Cell and Gene Therapy Manufacturing: The rise of cell and gene therapies is a major growth driver in the biologics CDMO market. These therapies hold the potential to treat previously incurable conditions, from genetic disorders to certain cancers. However, cell and gene therapy manufacturing is complex, requiring advanced techniques such as viral vector production, cell culture, and genetic engineering. CDMOs have responded by expanding their capabilities in cell and gene therapy manufacturing, offering specialized facilities and services that accelerate the development of these innovative therapies.

Adoption of Single-Use Bioprocessing Technologies: Single-use technologies (SUTs) are transforming biomanufacturing by reducing the need for sterilization, decreasing production time, and minimizing cross-contamination risks. CDMOs are increasingly adopting SUTs to improve operational efficiency and flexibility. The shift toward single-use systems is particularly beneficial for biologic drug production, as it allows for faster turnaround times and lower costs. This trend is likely to continue as CDMOs aim to meet the growing demand for biologics while maintaining high-quality standards and streamlined operations.

Increased Outsourcing by Small and Mid-Sized Biopharma Companies: Small and mid-sized biopharmaceutical companies are turning to CDMOs to navigate the high costs and regulatory complexities associated with biologics manufacturing. Outsourcing to CDMOs enables these companies to access advanced biomanufacturing capabilities without the significant capital expenditure required to build in-house facilities. This trend is bolstered by the CDMO market's expansion in specialized services, from clinical trial support to regulatory consulting, which are essential for smaller companies looking to bring innovative biologic drugs to market efficiently.

Market Segmentation

The biologics CDMO market is segmented by product, source, service, and geography, each offering unique insights into the market's growth trajectory:

By Product:

Monoclonal Antibodies (mAbs): The largest segment due to high demand for mAbs in treating cancer and autoimmune diseases.

Vaccines: A growing segment, driven by global immunization initiatives and the development of new vaccine technologies.

Recombinant Proteins: Widely used in chronic disease treatments, with growing applications in immunology and hematology.

By Source:

Mammalian: Dominates the market due to the suitability of mammalian cell lines in producing complex biologic drugs.

Microbial: A cost-effective option for simpler biologic products, particularly in the production of recombinant proteins.

By Geography:

North America: Leads the market, driven by a strong biopharmaceutical sector and high investment in R&D.

Europe: Strong growth due to supportive regulatory frameworks and a focus on advanced biologic therapies.

Asia-Pacific: Fastest-growing region, with increasing outsourcing from Western biopharma companies and rising local demand for biologics.

Get a Customized Report Tailored to Your Requirements, Visit - https://www.mordorintelligence.com/market-analysis/contract-packaging

Key Players in the Biologics CDMO Market

The biologics CDMO market is competitive, with key players investing heavily in expanding their service offerings, infrastructure, and technological capabilities. Prominent companies include:

Lonza Group:

Samsung Biologics

WuXi AppTec

Catalent, Inc.

Boehringer Ingelheim Biopharma

Fujifilm Diosynth Biotechnologies USA Inc.

These key players are continuously innovating and expanding their capabilities to meet the diverse needs of biopharmaceutical companies, contributing to the dynamic growth of the biologics CDMO market.

Industry Related Report

Pharmaceutical CMO Market: The Pharmaceutical CMO Market Report is Segmented by Service Type (Active Pharmaceutical Ingredient (API) Manufacturing (Small Molecule, Large Molecule, and High Potency API (HPAPI)), Finished Dosage Formulation (FDF) Development and Manufacturing (Solid Dose Formulation (Tablets and Others), Liquid Dose Formulation, and Injectable Dose Formulation), and Secondary Packaging) and Geography (North America (United States and Canada), Europe (United Kingdom, Germany, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, India, Japan, Australia, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentina, and Rest of Latin America), Middle East and Africa (United Arab Emirates, Saudi Arabia, South Africa, and Rest of Middle East and Africa)).

To know more visit this link: https://www.mordorintelligence.com/industry-reports/pharmaceutical-contract-manufacturing-organization-cmo-market

Pharmaceutical CDMO Market: The Report Covers Global Contract Development and Manufacturing Organization Market Share by Company. It is Segmented by Service Type CMO Segment (Active Pharmaceutical Ingredient (API) Manufacturing (Small Molecule, Large Molecule, High Potency (HPAPI)), Finished Dosage Formulation (FDF) Development and Manufacturing (Solid Dose Formulation (Tablets), Liquid Dose Formulation, Injectable Dose Formulation), and Secondary Packaging), Research Phase CRO Segment (Pre-Clinical, Phase I, Phase II, Phase III, Phase IV), Pharmaceutical CMO Geography (North America (United States and Canada), Europe (United Kingdom, Germany, France, Italy, and the Rest of Europe), Asia-Pacific (China, India, Japan, Australia, and the Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), Middle-East and Africa (United Arab Emirates, Saudi Arabia, South Africa, and the Rest of Middle-East and Africa)), and Pharmaceutical CRO Geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa).

To know more visit this link: https://www.mordorintelligence.com/industry-reports/pharmaceutical-contract-development-and-manufacturing-organization-cdmo-market

Personal Care Contract Manufacturing Market: The Personal Care Contract Manufacturing Market Report is Segmented by Service Type (R&D and Formulation, Manufacturing, and Packaging and Allied Services), Product Type (Skincare, Haircare, Make-Up and Cosmetics, and Other Product Types), and Geography (North America [United States, Canada], Europe [United Kingdom, France, Italy, and Rest of Europe], Asia-Pacific [China, Japan, India, South Korea, and Rest of Asia-Pacific], and Rest of the World).

To know more visit this link: https://www.mordorintelligence.com/industry-reports/global-personal-care-contract-manufacturing-market

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

This release was published on openPR.